Apeiron Investment Group, Ltd

Adds BPL-003 (mebufotenin benzoate intranasal) and VLS-01 (DMT buccal); upfront $6.75/share plus up to $2.50/share CVR tied to development, regulatory and DEA-rescheduling milestones.